



ASX ANNOUNCEMENT

16 February 2024

Cann to defend legal proceedings brought by Rua Bioscience Limited

16 February 2024 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) announced that on 15 February 2024 Rua Biosciences Limited (NZX:RUA) has commenced legal proceedings against Cannoperations Pty Ltd, a wholly owned subsidiary of Cann Group Limited.

The proceedings relate to a dispute between Cann and Rua in respect of a manufacturing and supply agreement, which Cann has sought to resolve amicably with Rua, but which has escalated over time.

Cann denies the claims brought against it and will vigorously defend the action.

Authorised for release by the Board of Directors, Cann Group Limited.

For all media enquiries please contact:

Jackson Paine
Corporate Communications Manager
+61 439 492 955
jackson.paine@canngrouponlimited.com

For all other information please contact:

Peter Koetsier
CEO
Cann Group Limited
+61 3 9095 7088
contact@canngrouponlimited.com

Steven Notaro
Head of Legal & Regulatory Affairs and
Company Secretary
Cann Group Limited
+61 3 9095 7088
steven.notaro@canngrouponlimited.com

About Cann Group

Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.canngrouponlimited.com | www.satipharm.com

Cann Group Limited

ACN 25 603 949 739, Australia
262-276 Lorimer Street, Port Melbourne 3207, Victoria, Australia
Tel +61 (0) 3 9095 7088 | www.canngrouponlimited.com